Omnes Capital's investments: AgomAb Therapeutics

Sector 
Pharma
Entry Date 
04/2019
Business 
Venture Capital

AgomAb Therapeutics

A biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues

AgomAb was founded through a collaboration between argenx and the University of Torino, Italy, based on the groundbreaking work of Paolo Michieli and his translational medicine team. The Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors.

Latest news